Multimodal Targeted Drug Delivery Strategies for Severe Acute Respiratory Syndrome (SARS): Advances in Nanocarriers, Inhaled Corticosteroids (ICSs), Novel Biologicals, Gene Therapy, Personalized Medicines, Approaches
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901814699360256 |
|---|---|
| author | Nilofar Raju Mujawar*, Manali Bhau Naik |
| author_facet | Nilofar Raju Mujawar*, Manali Bhau Naik |
| contents | <p><span>The cause of severe acute respiratory syndrome (SARS) is the SARS coronavirus (SARS-CoV), a viral respiratory disease that manifests as fever, coughing, dyspnoea, and pneumonia. Being near a confirmed or suspected case, or visiting a person who is affected, and by using laboratory techniques like RT-PCR or serology to find SARS-CoV RNA or antibodies They can be treated with a variety of medications, including oxygen therapy, immunomodulators, and bronchodilators. However, there are still certain issues with medication side effects and efficacy. Targeted therapeutics and accurate medication distribution methods are essential to therapy of various disorders in order to maximise therapeutic success while minimising systemic side effects. The function of drug delivery system in severe acute respiratory illness is main topic of this comprehensive review. In particular, new biologicals, Inhaled corticosteroids and gene therapy, Personalized medicine and drug delivery methods based on nanoparticles are all reviewed. We hope to offer comprehensive overview of the existing situation & potential upcoming developments for enhancing treatment leads to these challenging conditions through looking at the latest advancements & approaches within these fields.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15397975 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Multimodal Targeted Drug Delivery Strategies for Severe Acute Respiratory Syndrome (SARS): Advances in Nanocarriers, Inhaled Corticosteroids (ICSs), Novel Biologicals, Gene Therapy, Personalized Medicines, Approaches Nilofar Raju Mujawar*, Manali Bhau Naik Drug Delivery; Severe Acute Respiratory Syndrome; Nanoparticle-Based Drug Delivery Systems; Inhaled Corticosteroids; Novel Biologicals; Gene Therapy; Personalized Medicine. <p><span>The cause of severe acute respiratory syndrome (SARS) is the SARS coronavirus (SARS-CoV), a viral respiratory disease that manifests as fever, coughing, dyspnoea, and pneumonia. Being near a confirmed or suspected case, or visiting a person who is affected, and by using laboratory techniques like RT-PCR or serology to find SARS-CoV RNA or antibodies They can be treated with a variety of medications, including oxygen therapy, immunomodulators, and bronchodilators. However, there are still certain issues with medication side effects and efficacy. Targeted therapeutics and accurate medication distribution methods are essential to therapy of various disorders in order to maximise therapeutic success while minimising systemic side effects. The function of drug delivery system in severe acute respiratory illness is main topic of this comprehensive review. In particular, new biologicals, Inhaled corticosteroids and gene therapy, Personalized medicine and drug delivery methods based on nanoparticles are all reviewed. We hope to offer comprehensive overview of the existing situation & potential upcoming developments for enhancing treatment leads to these challenging conditions through looking at the latest advancements & approaches within these fields.</span></p> |
| title | Multimodal Targeted Drug Delivery Strategies for Severe Acute Respiratory Syndrome (SARS): Advances in Nanocarriers, Inhaled Corticosteroids (ICSs), Novel Biologicals, Gene Therapy, Personalized Medicines, Approaches |
| topic | Drug Delivery; Severe Acute Respiratory Syndrome; Nanoparticle-Based Drug Delivery Systems; Inhaled Corticosteroids; Novel Biologicals; Gene Therapy; Personalized Medicine. |
| url | https://doi.org/10.5281/zenodo.15397975 |